List of Excipients in Branded Drug ASCENIV

ASCENIV Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

ASCENIV is a 10% human immune globulin intravenous product from ADMA Biologics for primary humoral immunodeficiency in adults and adolescents aged 12 years and older. Its excipient system uses glycine, polysorbate 80, and water for injection. The commercial opportunity is less likely to come from a novel excipient alone than from improved protein stability, reduced infusion reactions, longer shelf life, lower container loss, and differentiated administration formats.

ASCENIV has biologic-product economics rather than conventional small-molecule generic economics. Plasma sourcing, donor qualification, viral clearance, manufacturing validation, cold-chain distribution, clinical comparability, and FDA licensure create the principal barriers to competition. Excipient innovations can strengthen the product franchise by supporting formulation patents, manufacturing know-how, device claims, and lifecycle extensions.

What excipients are used in ASCENIV?

ASCENIV contains glycine and polysorbate 80 in an aqueous formulation. The product is preservative-free and supplied as a 10% protein solution for intravenous administration. The labeled formulation has an acidic pH range of approximately 4.6 to 5.1 and is stored under refrigerated conditions [1].

Formulation element	ASCENIV role	Commercial significance
Human immunoglobulin G	Active biological ingredient	Determines potency, purity, aggregation, and clinical performance
Glycine	Stabilizing amino-acid excipient and buffering component	Supports protein stability during storage and processing
Polysorbate 80	Surfactant	Reduces surface-induced aggregation and protein loss
Water for injection	Vehicle	Supports intravenous administration
Preservatives	None	Reduces preservative-related tolerability concerns

ASCENIV is manufactured from human plasma collected from U.S. donors. The product’s formulation cannot be evaluated independently from its plasma fractionation and purification process. Immunoglobulin composition, aggregate burden, trace proteins, container interaction, and viral-clearance conditions all influence excipient performance.

How does ASCENIV’s excipient system support product stability?

Glycine and polysorbate 80 address different degradation pathways.

Glycine can reduce protein unfolding and support the stability of immunoglobulin molecules in solution. Its use is common in plasma-derived immunoglobulin products because it is compatible with intravenous administration and does not introduce the preservative concerns associated with some alternative excipients.

Polysorbate 80 limits adsorption to manufacturing equipment, tubing, filters, and container surfaces. It also reduces agitation-related aggregation during filling, shipping, and infusion preparation. The commercial risk is that polysorbates can undergo oxidation or hydrolysis, generating degradation products that may affect protein quality and particulate formation. That creates an opportunity for tighter control of raw-material quality, peroxide content, storage conditions, and interaction with container-closure systems.

The highest-value formulation work is therefore likely to involve:

• Lower aggregate formation after transport and repeated handling.
• Better control of subvisible particles.
• Reduced protein adsorption to infusion bags and tubing.
• Improved stability after vial puncture or preparation.
• Lower sensitivity to temperature excursions.
• Longer refrigerated shelf life.
• More consistent performance across plasma lots.

These improvements can support regulatory supplements, manufacturing controls, or patent claims if they produce measurable product or process advantages.

What formulation patents could protect ASCENIV?

ASCENIV’s commercial protection is more likely to involve a combination of biologic exclusivity, process patents, formulation patents, and trade secrets than a single broad excipient patent.

Potentially protectable subject matter includes:

Excipient concentration and ratio

Claims could cover defined concentrations of glycine and polysorbate 80, including concentration ranges that reduce aggregation or preserve immunoglobulin recovery. A defensible claim would generally need to link the composition to a measurable technical result, such as reduced high-molecular-weight species or improved stability after agitation.

Alternative surfactants

A lifecycle formulation could evaluate polysorbate 20, poloxamers, or other pharmaceutically acceptable surfactants. The commercial case would depend on demonstrating lower oxidation, lower particle formation, or improved storage performance without compromising tolerability.

Antioxidant and chelator systems

Formulations may investigate methionine, histidine, citrate, or chelating agents to control oxidative degradation. Such approaches require careful assessment because changes in ionic strength, pH, osmolality, or infusion tolerability can affect the final product.

Container-closure systems

Vials, elastomeric stoppers, coatings, infusion bags, and low-binding tubing can be claimed or protected through supplier know-how. Container interaction is commercially relevant for high-value biologics because even small levels of adsorption or leachables can affect batch release and shelf life.

Manufacturing and fill-finish processes

Process claims may cover the sequence and conditions for excipient addition, low-shear mixing, filtration, filling, hold times, and temperature control. These claims can be more difficult to design around when they are tied to a specific product-quality profile.

Public FDA labeling identifies the ASCENIV excipient system but does not establish a conventional Orange Book patent-expiration framework. Patent conclusions require review of ADMA Biologics’ issued patents, pending applications, assignments, and litigation records. The FDA label alone does not provide a complete patent estate.

When does ASCENIV lose exclusivity?

ASCENIV is a biologic licensed under the Public Health Service Act. It does not follow the Hatch-Waxman exclusivity structure used for ordinary small-molecule drugs.

ASCENIV received FDA approval in April 2019 for primary humoral immunodeficiency [2]. The reference product’s statutory biologic exclusivity period is generally 12 years from first licensure under the Biologics Price Competition and Innovation Act. On that basis, the principal reference-product exclusivity period runs to approximately April 2031, subject to the statutory first-licensure date and applicable regulatory calculations [3].

Protection type	ASCENIV relevance
FDA biologic exclusivity	Approximately 12 years from first licensure
Orange Book listing	Not the governing framework for ASCENIV
Purple Book status	Relevant reference-product and biosimilar framework
Formulation patents	May extend protection beyond regulatory exclusivity if valid and enforceable
Process patents	May constrain biosimilar or competing plasma-derived manufacturing
Trade secrets	Important for fractionation, purification, lot release, and stability controls

A biosimilar applicant may begin development before the end of the 12-year period, but commercial approval and launch remain subject to the BPCIA pathway, patent resolution, and regulatory approval.

What is the FDA and Orange Book status of ASCENIV?

ASCENIV is FDA-approved as a biologic product, not as a conventional small-molecule drug. The Orange Book is therefore not the principal source for ASCENIV’s exclusivity or patent information.

The relevant regulatory sources are:

• FDA biologics licensing records.
• The Purple Book.
• FDA approval letters and prescribing information.
• BPCIA patent-exchange and litigation records.
• USP and FDA manufacturing requirements for human plasma-derived products.

ASCENIV’s approved indication is primary humoral immunodeficiency in adults and adolescents 12 years and older. The labeled dose is generally 300 to 800 mg/kg administered every three to four weeks, with individualization based on clinical response and serum IgG levels [1].

What biosimilar and generic entry risks exist for ASCENIV?

ASCENIV does not face a traditional ANDA generic-launch pathway. A competing product would generally require a biologics license or biosimilar application, depending on the product’s regulatory strategy and reference-product relationship.

The technical entry barriers are significant:

1. Plasma supply must be qualified and scalable.
2. Donor screening and infectious-disease testing must satisfy FDA requirements.
3. The manufacturing process must produce a consistent immunoglobulin profile.
4. Viral inactivation and removal must be validated.
5. Aggregate and particulate levels must remain within specifications.
6. Clinical comparability must support the proposed indication and route.
7. Cold-chain logistics must protect product quality.
8. Commercial payers and infusion providers must accept the new product.

For ASCENIV, biosimilar substitution may also be less automatic than substitution for an interchangeable product. Pharmacy-level substitution depends on the product’s regulatory designation and state law. Hospital and specialty-infusion purchasing decisions may therefore matter more than retail pharmacy substitution.

The main competitive threat is likely to come from established IVIG manufacturers with existing plasma networks, rather than from a conventional generic company attempting to copy the formulation.

Which companies compete with ASCENIV?

ASCENIV competes in the U.S. intravenous immunoglobulin market against products including:

Product	Company	Broad competitive position
Gamunex-C	Grifols	Large established IVIG franchise with broad clinical use
Gammagard Liquid	Takeda	Major IVIG product with extensive provider familiarity
Privigen	CSL Behring	Large plasma-derived immunoglobulin platform
Panzyga	Takeda	IVIG competitor with U.S. commercial presence
Octagam	Octapharma	Established IVIG product with differentiated manufacturing platform
ASCENIV	ADMA Biologics	Focused product supported by ADMA’s plasma collection and manufacturing model

Excipient strategies differ across competing products. Glycine is common in IVIG formulations, while L-proline and other stabilizer systems are used in certain products. These differences affect pH, osmolality, storage, infusion experience, and sensitivity to aggregation.

A product’s excipient profile rarely determines market share by itself. Infusion reaction rates, supply reliability, payer access, dosing convenience, historical performance, and purchasing contracts usually carry greater commercial weight.

What commercial opportunities exist for ASCENIV excipients?

Lower-infusion-reaction positioning

A formulation with lower aggregate burden or improved particle control could support a differentiated tolerability profile. Any commercial claim would need clinical or postmarketing evidence rather than relying on excipient composition alone.

Extended shelf life

An increase in shelf life could reduce inventory write-offs for specialty pharmacies, hospitals, and infusion centers. The value is highest where products are purchased in multiple vial sizes and demand is difficult to forecast.

Excursion-resistant packaging

Improved stability under controlled temperature excursions could reduce distribution losses. The strategy would combine formulation work with vial, stopper, secondary packaging, and shipping-validation improvements.

Ready-to-use administration formats

Pre-filled or infusion-ready presentations could reduce preparation time and handling errors. Such products would require compatibility testing with infusion devices, bags, tubing, and pumps. Device and container claims could provide additional intellectual-property coverage.

Larger or smaller vial sizes

Vial-size optimization can reduce wastage because immunoglobulin dosing is weight-based. Smaller presentations may improve dose rounding, while larger presentations can reduce handling costs for high-dose patients. The optimal configuration depends on payer rules, infusion-center workflow, and patient weight distribution.

Subcutaneous or facilitated delivery

A subcutaneous version would represent a major lifecycle opportunity, but it would not be a simple excipient reformulation. It could require concentration changes, viscosity control, absorption-enabling technology, and a new clinical and regulatory package. Hyaluronidase-enabled delivery or high-concentration formulations could expand use outside infusion centers, but they would introduce new manufacturing and intellectual-property requirements.

Specialty-patient positioning

ASCENIV may have commercial value in patients who require reliable IVIG supply, have limited alternatives, or are managed through specialty infusion providers. A stable supply record can be a differentiator in a market exposed to plasma-collection constraints.

How strong is the ASCENIV patent estate?

The product’s practical protection is stronger than an excipient-only analysis suggests because the relevant barriers include plasma sourcing, manufacturing validation, regulatory exclusivity, process controls, and clinical history.

Patent strength should be assessed across five categories:

Category	Strategic value
Composition patents	Protect excipient ranges and product-quality attributes
Process patents	Cover fractionation, purification, viral clearance, and filtration
Container patents	Protect low-binding and stability-enhancing presentations
Method-of-use patents	Protect defined patient populations or dosing approaches
Trade secrets	Protect operating ranges, release controls, and process parameters

A weak formulation patent covering only routine use of glycine or polysorbate 80 may face obviousness and enablement challenges. A stronger patent would connect a defined formulation to unexpected stability, lower aggregation, improved recovery, or reduced infusion-related events.

Method-of-use patents may have limited value for a product whose principal approved use is broad replacement therapy. They become more commercially relevant if clinical evidence supports differentiated dosing, selected patient populations, or reduced hospitalization and infusion burden.

What litigation and Paragraph IV risks affect ASCENIV?

Paragraph IV litigation is associated with ANDA applications for small-molecule products. It is not the standard pathway for ASCENIV because ASCENIV is a biologic.

The relevant legal risks are:

• BPCIA patent litigation involving a biosimilar applicant.
• Patent infringement claims against competing biologic manufacturers.
• Inter partes review or post-grant challenges against formulation or process patents.
• Trade-secret disputes involving plasma-derived manufacturing.
• Contract disputes involving plasma suppliers and specialized manufacturing partners.

No conventional Orange Book Paragraph IV launch timetable governs ASCENIV. A competing biologic could still create market pressure before statutory exclusivity expires through development, contracting, and payer engagement.

How does ASCENIV compare with other IVIG products?

ASCENIV’s commercial profile is defined by its focused indication, plasma-derived manufacturing platform, and 10% intravenous presentation. Compared with larger IVIG franchises, its opportunity is to compete on supply reliability, provider confidence, product quality, and targeted lifecycle development.

The most defensible commercial strategy is a layered one:

1. Preserve the current glycine-polysorbate formulation through tight quality controls.
2. Develop lower-aggregation and lower-particle variants.
3. Protect improved formulations with composition and process claims.
4. Improve vial sizing and infusion compatibility.
5. Evaluate longer shelf life and excursion-resistant packaging.
6. Consider subcutaneous or higher-concentration presentations only where clinical and manufacturing economics support development.

Key Takeaways

• ASCENIV uses glycine, polysorbate 80, and water for injection in a preservative-free 10% IVIG formulation.
• Glycine supports protein stability; polysorbate 80 reduces surface adsorption and agitation-related aggregation.
• The main commercial opportunity is improved stability, tolerability, packaging, and administration convenience.
• ASCENIV is governed by the biologic and Purple Book framework, not the conventional Orange Book generic framework.
• FDA approval occurred in April 2019, placing the approximate 12-year biologic exclusivity endpoint in April 2031.
• A conventional ANDA generic and Paragraph IV launch are not the expected competitive pathways.
• Biosimilar entry is constrained by plasma sourcing, manufacturing complexity, comparability requirements, and supply-chain controls.
• Formulation, process, container, and lifecycle patents can supplement regulatory exclusivity.
• The strongest formulation claims would link excipient composition to demonstrated improvements in aggregation, particles, shelf life, or infusion performance.
• Competitive differentiation will depend more on supply reliability, payer access, infusion outcomes, and manufacturing scale than on excipient novelty alone.

FAQs About ASCENIV Excipient and Commercial Strategy

Can ASCENIV be reformulated without conducting new clinical trials?

Some formulation or manufacturing changes may qualify for a chemistry, manufacturing, and controls supplement if product comparability is adequately demonstrated. A material change in concentration, route, excipient system, or delivery platform may require additional clinical evidence.

Does polysorbate 80 create a patent opportunity for ASCENIV?

Polysorbate 80 alone is unlikely to provide strong exclusivity because it is widely used. A patent opportunity may exist where a specific concentration, quality specification, container system, or manufacturing condition produces an unexpected stability or particle-control result.

Could ASCENIV be converted to subcutaneous administration?

Potentially, but a subcutaneous version would require substantial development. The program would need to address concentration, viscosity, injection volume, absorption, local tolerability, device compatibility, and clinical efficacy.

Are ASCENIV revenues exposed to small-molecule generic erosion?

No conventional small-molecule generic erosion mechanism applies. Revenue exposure is more closely tied to competing IVIG products, biosimilar development, plasma supply, payer contracting, and provider switching.

Which excipient strategy offers the highest commercial value?

A stability-and-administration strategy is likely to have the highest value: lower aggregation, reduced particles, longer shelf life, improved temperature-excursion tolerance, and packaging that minimizes infusion preparation and product loss.

References

1. U.S. Food and Drug Administration. (2019). ASCENIV prescribing information. ADMA Biologics, Inc.
2. U.S. Food and Drug Administration. (2019). FDA approves ASCENIV for primary humoral immunodeficiency.
3. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
5. ADMA Biologics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.